References
- World Health Organization. Coronavirus disease (COVID-19). https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200831-weekly-epi-update-3.pdf?sfvrsn=d7032a2a_4. Accessed 2020 Aug 30.
- Wang Q, Wong G, Lu G, et al. MERS-CoV spike protein: targets for vaccines and therapeutics. Antiviral Res. 2016;133:165–177.
- Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263.
- Chan JF, Kok K, Zhu Z, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;28(1):221–236.
- Hossain MJ, Kuddus MR, Rahman SMA. Knowledge, attitudes, and behavioral responses toward COVID-19 during early phase in Bangladesh: a questionnaire-based study. Asia Pac J Public Health. 2020. DOI:https://doi.org/10.1177/1010539520977328.
- Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: drug repurposing, clinical trials and recent advancements. Life Sci. 2020;256:117883.
- Yin W, Yin W, Mao C, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. Science. 2020;368(6498):1499–1504.
- Ko W, Rolain J, Lee N, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agent. 2020;55(4):105933.
- Leung NHL, Chu DKW, Shiu EYC, et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat Med. 2020;26(5):676–680.
- Chen N, Zhou M, Dong X, et al. COVID-19-Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
- Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6(1). DOI:https://doi.org/10.1038/s41421-020-0153-3.
- Chen J. COVID-19-Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69–71.
- Li G, Clercq ED. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150.
- Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
- Becker RC. Covid-19 treatment update: follow the scientific evidence. J Thromb Thrombolysis. 2020;50(1):43–53.
- Misra DP, Agarwal V, Gasparyan AY, et al. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055–2062.
- Al-Tawfiq JA, Al-Homoud AH, Memish ZA. COVID-19-Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615.
- Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS- 5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018;9(2). DOI:https://doi.org/10.1128/mBio.00221-18.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(396):eaal3653.
- Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for covid-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315–331.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.
- Yethindra V. Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: the expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. Int J Res Pharm Sci. 2020;11(SPL1):1–6.
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2012. DOI:https://doi.org/10.1038/s41467-019-13940-6.
- Lu C, Chen M, Chang Y. Potential therapeutic agents against COVID-19 : what we know so far. J Chin Med Assoc. 2020. DOI:https://doi.org/10.1097/JCMA.0000000000000318.
- Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327–2336.
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020;383(19):1827–1837.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — preliminary Report. N Engl J Med. 2020;383(19):1813–1826. .
- Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with p-glycoprotein inhibitors. Clin Infect Dis. 2020. DOI:https://doi.org/10.1093/cid/ciaa883.
- FDA news release. COVID-19 Update: FDA broadens emergency use authorization for veklury (remdesivir) to include all hospitalized patients for treatment of COVID-19. https://www.fda.gov/news-events/press-announcements/covid-19-update-fda-broadens-emergency-use-authorization-veklury-remdesivir-include-all-hospitalized#:~:text=Today%2C%20as%20part%20of%20its,laboratory%2Dconfirmed%20COVID%2D19%2C. Accessed 2020 Aug 28.
- Shiraki K, Daikoku T. Pharmacology & Therapeutics Favipiravir, an anti-in fl uenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512.
- Bo TM, Basu F, Sta RG, et al. Synthesis of [18F] favipiravir and biodistribution in c3h/hen mice as assessed by positron emission tomography. Sci Rep. 2019. DOI:https://doi.org/10.1038/s41598-018-37866-z.
- Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces Ind. 2020;76(4):370–376.
- Jochmans D, Van NS, Smits SL, et al. Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human etapneumovirus in Hamsters. Antimicrob Agents Chemother. 2016;60(8):4620–4629.
- Abdelnabi R, Theresa A, De MS, et al. Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): key role of the F1 motif of the viral polymerase. J Virol. 2017;91(12). DOI:https://doi.org/10.1128/JVI.00487-17.
- Kiso M, Takahashi K, Sakai-tagawa Y, et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA. 2010;107(2):882–887.
- Furuta Y, Takahashi K, Kuno-maekawa M, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother. 2005;49(3):981–986.
- Khambholja K, Asudani D. Fav-Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis. 2020;35:101710.
- Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19 : an open-label control study. Engineering (Beijing). 2020. DOI:https://doi.org/10.1016/j.eng.2020.03.007.
- Chen C, Huang J, Cheng Z, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv. 2020. DOI:https://doi.org/10.1101/2020.03.17.20037432.
- COVID-19: glenmark’s favipiravir shows encouraging results in phase 3 clinical trial. The Indian Express. https://www.newindianexpress.com/nation/2020/jul/23/covid-19-glenmarks-favipiravir-shows-encouraging-results-in-phase-3-clinical-trial-2173500.html. Accessed 2020 Jul 23.
- Trial site news. The Dhaka trial: Clear-cut evidence favipiravir effective against COVID-19 with compelling results. https://www.trialsitenews.com/the-dhaka-trial-clear-cut-evidence-favipiravir-effective-against-covid-19-with-compelling-results/. Accessed 2020 Jul 10
- Trial site news. Russia ministry of health approves avifavir (favipiravir) for COVID-19 patients—cuts duration of illness by over 50 %. https://www.trialsitenews.com/russia-ministry-of-health-approves-avifavir-favipiravir-for-covid-19-patients-cuts-duration-of-illness-by-over-50/. Accessed 2020 Jun 1.
- Kaplan SS, Hicks CB. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother. 2005;450(9):1573–1585.
- Podzamczer D, King MS, Klein CE, et al. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin Trials. 2007;8(4):193–204.
- Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir : a multicentre retrospective matched. Hong Kong Med J. 2003;9:399–406.
- Chu C, Cheng V, Hung I, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252–256.
- Wilde AHD, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875–4884.
- Nutho B, Mahalapbutr P, Hengphasatporn K, et al. Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms. Biochemistry. 2020;59(18):1769–1777.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Eng J Med. 2020;382(19):1787–1799.
- Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir – ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19 : an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695–1704.
- RECOVERY collaboartive group. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020; https://doi.org/10.1016/S0140-6736(20)32013-4.
- Osborne V, Davies M, Lane S, et al. Lopinavir-ritonavir in the treatment of COVID-19: A dynamic systematic benefit-risk assessment. Drug Saf. 2020;43(8):809–821.
- World Health Organization. WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 2020 Jul 4.
- Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23(1):275–306.
- De Andrea M, Ravera R, Gioia D, et al. The interferon system: an overview. Eur J Paediatr Neurol. 2002;6(SUPPL. 1):A41–A46.
- Jakimovski D, Kolb C, Ramanathan M, et al. Interferon β for multiple sclerosis. Cold Spring Harbor Perspect Med. 2018;8(11):1–20.
- Morgenstern B, Michaelis M, Baer PC, et al. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2020;326(4):905–908.
- Falzarano D, De WE, Martellaro C, et al. Inhibition of novel β coronavirus replication by a combination of interferon- α2b and ribavirin. Sci Rep. 2013;3(1). DOI:https://doi.org/10.1038/srep01686
- Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090–1095.
- Lokugamage KG, Hage A, de Vries M, et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. bioRxiv. 2020. DOI:https://doi.org/10.1101/2020.03.07.982264.
- Sallard E, Lescure FX, Yazdanpanah Y, et al. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791.
- Qiu H, Wu J, Hong L, et al. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis. 2020;20(6):689–696.
- Yuan J, Zou R, Zeng L, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflamm Res. 2020;69(6):599–606.
- Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front Immunol. 2020;11. DOI:https://doi.org/10.3389/fimmu.2020.01061.
- Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94.
- E-I P, Borisevich V, Halfmann P, et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. J Virol. 2016;90(6):3086–3092.
- Hulseberg E, Feneant L, Wijs KMS, et al. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol. 2019;93(8). DOI:https://doi.org/10.1128/JVI.02185-18.
- Fink SL, Vojtech L, Wagoner J, et al. The Antiviral drug arbidol inhibits zika virus. Sci Rep. 2018;8(1). DOI:https://doi.org/10.1038/s41598-018-27224-4.
- Liu Q, Xiong HR, Lu L, et al. Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol Sin. 2013;34(8):1075–1083.
- Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6(1). DOI:https://doi.org/10.1038/s41421-020-0169-8.
- Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020. DOI:https://doi.org/10.1186/s40779-020-0233-6.
- Lima WG, Brito JCM, Overhage J. Nizer WS da C. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Arch Virol. 2020;165:(8):1729–1737. .
- Yang C, Ke C, Yue D, et al. Effectiveness of arbidol for COVID-19 prevention in health professionals. Front Public Health. 2020;8. DOI:https://doi.org/10.3389/fpubh.2020.00249.
- Wang Z, Yang B, Li Q, et al. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71(15):769–777.
- Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020;81(1):e21-e23.
- Lian N, Xie H, Lin S, et al. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917–921.
- Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: A retrospective cohort study. J Infect. 2020;81(1):e1-e5.
- Salata C, Calistri A, Parolin C, et al. Antiviral activity of cationic amphiphilic drugs. Expert review of anti-infective therapy. 2017;15:483–492.
- Vincent MJ, Bergeron E, Benjannet S, et al. spread. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2(1):69.
- Colson P, Rolain JM, Lagier JC, et al. COVID-19-Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020;55(4):105932.
- Keyaerts E, Li S, Vijgen L, et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrob Agents Chemother. 2009;53(8):3416–3421.
- Gao J, Tian Z, Yang X. Breakthrough : chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2. Clin Infect Dis. 2020;71(15):732–739.
- Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938.
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020. DOI:https://doi.org/10.1038/s41421-020-0156-0.
- Sahraei Z, Shabani M, Shokouhi S, et al. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents. 2020;55(4):105945.
- Gautret P, Lagier C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
- Andreani J, Bideau ML, Duflot I, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228.
- Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19 Use of these drugs is premature and potentially harmful. BMJ. 2020;m1432. https://doi.org/10.1136/bmj.m1432.
- Geleris J, Sun Y, Platt J, et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020; 382(25): 2411–2418. .
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;m1849. DOI:https://doi.org/10.1136/bmj.m1849
- Rizzo E. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(7):1153–1156.
- Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856.
- Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;178:104787.
- Chaccour C, Hammann F, Ram S, et al. Ivermectin and COVID-19: keeping rigor in times of urgency. Am J Trop Med Hyg. 2020;102(6):1156–1157.
- Navarro M, Campurbi D, Requena-mendez A, et al. Safety of high-dose ivermectin: a systematic review and meta-analysis. J Antimicrob Chemother. 2020;75(4):827–835.
- Lespine A, Alvinerie M, Sutra JF, et al. Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat. Vet Parasitol. 2005;128(3–4):251–260.
- Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-on therapy in COVID-19 management (Pilot Trial). medRxiv. 2020. DOI:https://doi.org/10.1101/2020.07.07.20145979.
- Rossingnol JF. Nitazoxanide: A first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
- Rossingnol JF. COVID-19 and MERS-Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health. 2020;9(3):227–230.
- Haffizulla J, Hartman A, Hoppers M, et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated infl uenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial. Lancet Infect Dis. 2014;14(7):609–618.
- Kelleni MT. Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. Pharmacol Res. 2020;157:104874.
- Australian Medicines Handbook section 15.1.2. Immunosuppressants. Aust Prescr. 2019;42:34–35.
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574.
- Sorrell FJ, Szklarz M, Azeez KRA, et al. Family-wide structural analysis of human numb- associated protein kinases. Structure. 2016;24(3):401–411.
- Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
- Smolen JS, Genovese MC, Takeuchi T, et al. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2019;46(1):7–18.
- Favalli EG, Biggioggero M, Maioli G, et al. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20(9):1012–1013.
- Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment?-Authors’ reply. Lancet Infect Dis. 2020;20(9):1013–1014.
- Wei YY, Wang RR, Zhang DW, et al. Risk factors for severe COVID-19: evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81(1):e89–e92.
- Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
- Abdallah H, Hsu JC, Lu P, et al. Pharmacokinetic and pharmacodynamic analysis of subcutaneous tocilizumab in patients with rheumatoid arthritis from 2 randomized, controlled trials: SUMMACTA and BREVACTA. J Clin Pharmacol. 2017;57(4):459–468.
- Brandão F, Coelho P, Pinto P, et al. Ticilizumab-A new step in Rheumatoid Arthiritis treatment. Acta Rheumatol Port. 2010;35:302–312.
- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
- Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970–10975.
- Moore BJB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–474.
- Alattar R, Ibrahim TBH, Shaar SH, et al. Tocilizumab for the treatment of severe coronavirus disease 2019. J Med Virol. 2020;92(10):2042–2049.
- Luo P, Liu Y, Qiu L, et al. Tocilizumab treatment in COVID ‐ 19: A single center experience. J Med Virol. 2020;92(7):814–818.
- Kewan T, Covut F, Al–Jaghbeer MJ, et al. Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study. EClinicalMedicine. 2020;24:100418.
- Capra R, De Rossi N, Mattioli F, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020;76:31–35.
- Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-centre study. Expert Rev Anti Infect Ther. 2020;1–8. DOI:https://doi.org/10.1080/14787210.2020.1800453.
- Toniati P, Piva M, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568.
- Guaraldi G, Meschiari M, Cozzi-lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020;2(8):e474–e484. 2020;9913(20):1–11.
- Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia. [cited 2020 Jul 29]. Available from: https://www.roche.com/investors/updates/inv-update-2020-07-29.htm.
- Atal S, Fatima Z. IL-6 inhibitors in the treatment of serious COVID-19: a promising therapy? Pharmaceut Med. 2020;34:223–231.
- Zhang S, Li L, Shen A, et al. Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig. 2020;40(6):511–518.
- Baskar S, Klein AL, Zeft A. The use of IL-1 receptor antagonist (anakinra) in idiopathic recurrent pericarditis: a narrative review. Cardiol Res Pract. 2016. DOI:https://doi.org/10.1155/2016/7840724.
- Roshanravan N, Seif F, Ostadrahimi A, et al. Targeting cytokine storm to manage patients with COVID-19: A mini-review. Arch Med Res. 2020;51(7):608–612. .
- Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79(10):1381–1382.
- Navarro‐Millán I, Sattui S, Lakhanpal A, et al. Use of anakinra to prevent mechanical ventilation in severe covid‐19: A case series. Arthritis Rheumatol. 2020;72(12):1990–1997.
- Day JW, Fox TA, Halsey R, et al. Interleukin-1 blockade with anakinra in acute leukaemia patients with severe COVID-19 pneumonia appears safe and may result in clinical improvement. Br J Haematol. 2020;190(2):e80–e83.
- Dimopoulos G, Mast QD, Markou N, et al. Favorable anakinra responses in severe COVID-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020;28:117–123.
- Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–e400.
- Pontali E, Volpi S, Antonucci G, et al. Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020;146(1):213–215.
- Filocamo G, Mangioni D, Tagliabue P, et al. Use of anakinra in severe COVID-19: A case report. Int J Infect Dis. 2020;96:607–609.
- Franzetti M, Pozzetti U, Carugati M, et al. Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. Int J Infect Dis. 2020;97:215–218.
- Karadeniz H, Yamak BA, Özger HS, et al. Anakinra for the treatment of COVID-19-associated pericarditis: a case report. Cardiovasc Drugs Ther. 2020;34(6):883–885.
- González-García A, García-Sánchez I, Lopes V, et al. Successful treatment of severe COVID-19 with subcutaneous anakinra as a sole treatment. Rheumatology. 2020;59(8):2171–2173.
- King A, Vail A, O’Leary C, et al. Anakinra in COVID-19: important considerations for clinical trials. Lancet Rheumatol. 2020;2(7):e379–e381.
- Stockman LJ, Bellamy R, Garner P, et al. Review of Treatment Effects. PLOS Med. 2006;3(9):e343.
- Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006;129(6):1441–1452.
- Siemieniuk RAC, Meade MO, Alonso-coello P, et al. Corticosteroid therapy for patients hospitalized with community- acquired pneumonia: A systematic review and meta-analysis. Ann Inter Med. 2017;163(7):519–528.
- Lee N, Chan KCA, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–309.
- Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767.
- Xiao JZ, Ma L, Gao J, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Zhonghua Nei Ke Za Zhi. 2004;43:179–182.
- Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–475.
- Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684.
- Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):1–11.
- Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: A systematic review of the literature. Front Med. 2020;7. DOI:https://doi.org/10.3389/fmed.2020.00170.
- Ledford H. Coronavirus breakthrough: dexamethasone is first drug shown to save lives. Nature. 2020. DOI:https://doi.org/10.1038/d41586-020-01824-5.
- RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19-preliminary Report. N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2021436.
- WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19 patients#:~:text=The%20World%20Health%20Organization%20(WHO,critically%20ill%20with%20COVID%2D19. Accessed 2020 Jun 16.
- Hui DSC, Wong GWK. Advancements in the battle against severe acute respiratory syndrome. Expert Opin Pharmacother. 2004;5(8):1687–1693.
- Rojas M, Rodríguez Y, Monsalve DM, et al. Autoimmunity Reviews Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
- Hampton T. Blood Transfusions for Flu Pandemic? JAMA. 2006. DOI:https://doi.org/10.1001/jama.296.15.1827.
- Arabi YM, Hajeer AH, Luke T, et al. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerg Infect Dis. 2016;22(9):1554–1561.
- Cheng Y, Wong R, Soo YOY, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44–46.
- Griensven JV, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016;374(1):33–42.
- Beigel JH, Tebas P, Bajwa E, et al. Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study. Lancet Respir Med. 2017;5(6):500–511.
- Beigel JH, Aga E, Cho J, et al. Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. Lancet Respir Med. 2019;7(11):941–950.
- Zeng QL, Yu ZJ, Gou JJ, et al. Effect of convalescent plasma therapy on viral shedding and survival in patients with coronavirus disease 2019. J Infect Dis. 2020;222(1):38–43.
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490–9496.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with covid-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589.
- Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;158(1):e9–e13.
- Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020;92(10):1890–1901.
- Sridevi K, Munjal A, Chandran A, et al. Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review. Ann Clin Lab Res. 2020;8:1–6.
- Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening covid-19 a randomized clinical trial. JAMA. 2020;324(5):1–11.
- Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID ‐ 19: systematic review. J Med Virol. 2020;92(9):1475–1483.
- Sheridan C. Convalescent serum lines up as first-choice treatment for coronavirus. Nat Biotechnol. 2020;38(6):655–658.
- Hoffmann M, Kleine-weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
- Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020;76:14–20.
- Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125:21–38.
- Soler MJ, Barrios C, Oliva R, et al. Pharmacologic modulation of ACE2 expression. Curr Hypertens Rep. 2008;10(5):410–414.
- Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–879.
- Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.
- Jarcho JA, Ingelfinger JR, Hamel MB, et al. Inhibitors of the Renin–Angiotensin–Aldosterone System and Covid-19. N Engl J Med. 2020;382(25):2462–2464.
- Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens. 2020;38(5):781–782.
- Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020;81(5):537–540.
- de Vries AAF. Renin-angiotensin system inhibition in COVID-19 patients. Netherlands Hear J. 2020;28(7–8):396–405.
- De AFJ, Rodríguez-martín S, Lerma V, et al. Use of renin–angiotensin–aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705–1714.
- Bean DM, Kraljevic Z, Searle T, et al. Angiotensin-onverting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail. 2020;22(6):967–974.
- Li J, Wang X, Chen J, et al. Association of Renin-Angiotensin System Inhibitors with Severity or Risk of Death in Patients with Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiol. 2020;5(7):1–6.
- Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431–2440.
- Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of covid-19. N Engl J Med. 2020;382(25):2441–2448.
- Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681.
- Yamamoto M, Matsuyama S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother. 2016;60(11):6532–6539.
- Ko M, Jeon S, Ryu W-S, et al. Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate. bioRxiv. 2020. DOI:https://doi.org/10.1101/2020.05.12.090035.
- Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6):e00754–20.
- Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses. 2020;12(6):629.
- Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID-19. J Thromb Haemost. 2020;18(6):1521–1522.
- Doi K, Ikeda M, Hayase N, et al. COVID-UTH study group. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series. Crit Care. 2020;24:(1):20–23.
- Griffin MO, Fricovsky E, Ceballos G, et al. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010;299(3):C539–48.
- Rothan HA, Mohammed Z, Paydar M, et al. Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol. 2014;159(4):711–718.
- Michaelis M, Kleinschmidt MC, Doerr HW, et al. Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J Antimicrob Chemother. 2007;60(5):981–986.
- Francini E, Miano ST, Fiaschi AI, et al. Doxycycline or minocycline may be a viable treatment option against SARS-CoV-2. Med Hypotheses. 2020;144. DOI:https://doi.org/10.1016/j.mehy.2020.110054.
- Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother. 2016;60(8):4433–4441.
- Chukwudi CU, Good L. Interaction of the tetracyclines with double-stranded RNAs of random base sequence: new perspectives on the target and mechanism of action. J Antibiot. 2016;69(8):622–630.
- Singh H, Kumar A, Chauhan P. Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. Expert Rev Anti Infect Ther. 2020;18(10):997–1003. .
- Yates PA, Newman SA, Oshry LJ, et al. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020;14:1–5.
- Conforti C, Giuffrida R, Zalaudek I, et al. Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL −6 in COVID −19 outbreak. Dermatol Ther. 2020;33(4). https://doi.org/10.1111/dth.13437.
- Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDcases. 2020;21:e00864.